




Eliglustat

Revised: April 20, 2020.

CASRN: 491833-29-5



Drug Levels and Effects

Summary of Use during Lactation

Because there is no published experience with eliglustat during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Alglucerase, Imiglucerase, Taliglucerase Alfa

References

1. Balwani M, Burrow TA, Charrow J, et al. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. *Mol Genet Metab.* 2016;117:95–103. PubMed PMID: 26387627.

Substance Identification

Substance Name

Eliglustat

CAS Registry Number

491833-29-5

Drug Class

Breast Feeding

Lactation

Enzyme Inhibitors

Glycoside Hydrolase Inhibitors